2 nd published peer reviewed paper in the last month supporting the use of geneType, on the back of the ASX release dated February 9, 2023. Utilised a prospective cohort of more than 200,000 women ...
Large prospective study to evaluate a non-invasive prenatal screening test Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of EDEN, a ...
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics, Inc, a biotechnology company making cardiovascular disease prevention and early detection more accessible, personalized and precise, announces the launch ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of EDEN, a large, multi-center prospective study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results